FDA seeks support for reorganization of cancer programs, but debate continues.
In a letter, ASCO reaffirms its views on oncology consolidation at FDA.
Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.
Board approves continuation of partnerships between minority institutions and cancer centers for research, training, and outreach.
Duke recruits Judd Moul as chief of urology.
Foundation offers funds for mesothelioma research.
Other NCI funding opportunities listed.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives - David Gius assumes role of director of the University of Cincinnati Cancer Center
